Cadrenal Therapeutics, Inc. (CVKD)

NASDAQ: CVKD · Real-Time Price · USD

7.95

-0.33 (-3.99%)

Mar 9, 2026, 3:35 PM EDT - Market open

Cadrenal Therapeutics Employees

Cadrenal Therapeutics had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.

Employees

4

Change (1Y)

n/a

Growth (1Y)

n/a

Revenue / Employee

n/a

Profits / Employee

-$3,596,410

Market Cap

18.59M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	4	0	-
Dec 31, 2023	4	1	33.33%
Dec 31, 2022	3	-	-

Related Stocks

Company Name	Employees
Citius Pharmaceuticals	23
Reviva Pharmaceuticals Holdings	14
VYNE Therapeutics	13
Genenta Science	13
Allarity Therapeutics	7
Intensity Therapeutics	7
Lexaria Bioscience	7
NanoViricides	7

Employee Rankings

CVKD News

7 days ago - Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion - GlobeNewsWire
13 days ago - Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement - GlobeNewsWire
2 months ago - Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor - GlobeNewsWire
2 months ago - Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - Accesswire
2 months ago - Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - Accesswire
2 months ago - Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 - GlobeNewsWire
3 months ago - Cadrenal's Quiet Expansion Play Is Starting to Get Loud - Accesswire
3 months ago - Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - Accesswire